My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

128.84 -0.42 (-0.32%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

Today 17:45 EDT

Via Benzinga

Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗

Today 9:17 EDT

This fixed-income ETF offers diversified bond exposure and a flexible strategy focused on income and sector allocation.

Via The Motley Fool

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Today 8:30 EDT

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

April 28, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗

April 25, 2026

Via Chartmill

Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗

April 20, 2026

Via Chartmill

3 Healthcare Stocks That Pay You While You Wait for the Growth ↗

April 27, 2026

It may not seem like it at first, but these dividends are safe.

Via The Motley Fool

Topics Intellectual Property

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

April 24, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Via StockStory

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

What's Going On With Arcus Biosciences Stock On Wednesday? ↗

April 22, 2026

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.

Via Benzinga

Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗

April 20, 2026

Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs.

Via Investor's Business Daily

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

April 14, 2026

Via Benzinga

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

April 14, 2026

From Gilead Sciences, Inc.

Via Business Wire

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

April 14, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

April 12, 2026

Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers....

Via StockStory

Topics Artificial Intelligence

Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗

April 10, 2026

Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings.

Via Benzinga

Topics Artificial Intelligence

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗

April 09, 2026

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development.

Via Benzinga

Topics Artificial Intelligence

Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗

April 07, 2026

Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.

Via Benzinga

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Gilead Extends Tender Offer to Acquire Arcellx

April 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences's Q1 2026 Earnings: What to Expect

April 01, 2026

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Via Barchart.com

Topics ETFs Workforce

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Options Action: Naked Put Trade Ideas for March 31

March 31, 2026

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

Via Barchart.com

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗

March 30, 2026

This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

March 30, 2026

Via Benzinga

Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗

March 24, 2026

Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.

Via Benzinga

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.